AUS
NZ
UK
CA
USA
IND
_07_03_2026_03_50_21_133108.jpg)
_10_04_2024_16_38_50_427275.jpg)
Global Health Limited (ASX:GLH), a Melbourne-based healthcare software provider, announced customer receipts of $9.532 million for the 12 months ending June 2026, reflecting a 12.6% increase from the previous year. The company completed its extensive technology upgrade to a software-as-a-service (SaaS) model after investing approximately $10 million in research and development over four years. It also outlined a strategic focus on revenue scaling and international market expansion in the upcoming financial year.
Key Points
- Global Health Limited (ASX:GLH) is an ISO27001-certified healthcare software company based in Melbourne, Victoria, offering case management, electronic medical records, practice management, and patient portal solutions.
- The company recorded a 12.6% rise in customer receipts to $9.532 million for the 12 months ending 30 June 2026, up from $8.463 million in the prior year.
- Operating and investing cash outflows decreased by 30% to $812,000 for the year to June 2026, down from $1.147 million previously, driven by workforce optimisation and AI integration across all departments.
- Global Health finalized its multi-year SaaS platform transition, deploying 5 new sites and upgrading 3 existing customers to the SaaS model in the June quarter; recurring SaaS revenue now accounts for 31.2% of total annual recurring revenue, rising from 27.8% the previous year.
- The company achieved positive cash-basis EBITDA in both March and June quarters and aims to sustain EBITDA profitability from FY2027 onward.
- Investors should watch the company’s progress on international expansion, upcoming Convertible Notes maturity in June and July 2027, and the shift from on-premises licenses to recurring SaaS subscriptions.
Customer Receipt Growth and Quarterly Performance to June 2026
Global Health Limited reported customer receipts totaling $9.532 million for the 12 months ending 30 June 2026, marking a 12.6% increase compared to $8.463 million in the prior corresponding period. Specifically, customer receipts for the June quarter reached $2.519 million. Data covering eight consecutive quarters from September 2024 through June 2026 shows quarterly fluctuations but an overall upward trend on a rolling 12-month basis.
This growth reflects an expanding user base and the company’s ongoing shift toward recurring revenue models. SaaS and monthly recurring revenue (MRR) now represent 31.2% of total annual recurring revenue (ARR), up from 27.8% the previous financial year. This transition away from legacy on-premises licenses toward subscription-based revenue is a strategic priority for Global Health.
Completion of Four-Year SaaS Technology Upgrade
In the June 2026 quarter, Global Health completed its major technology platform upgrade, concluding a multi-year R&D program with an investment of about $10 million over four years. Key technical milestones include consolidating three separate client-server applications into a single multi-tenanted, configurable SaaS platform; integrating the Heidi Scribe AI platform into both the MasterCare Plus SaaS and MasterCare EMR on-premises applications with market release completed; and incorporating HotHealth’s digital front door patient portal and ReferralNet secure messaging into Best Practice practice management systems, also released during the quarter.
Additional releases included a comprehensive user interface, experience, and technology upgrade of the Lifecard Personal Health Record solution, currently in final quality assurance and expected for release in August 2026. The company also launched Theatre Management and Bed Flow productivity platforms tailored for overnight and day hospital operations. During the quarter, 5 new customer sites went live with MasterCare Plus SaaS deployments, and 3 existing customers migrated from legacy on-premises systems to the SaaS platform.
30% Reduction in Operating Cash Outflows via AI and Workforce Optimisation
Global Health reported operating and investing cash outflows of $812,000 for the 12 months to June 2026, a 30% reduction from $1.147 million in the prior year. This improvement was driven by staff reductions and contractor cost savings enabled by artificial intelligence adoption across all departments, including sales, marketing, feature design, development, testing, onboarding, and support.
Net cash from operating activities in the June 2026 quarter was $70,000. The company plans to reduce its R&D budget by approximately $700,000 to $1.1 million in FY2027, down from $1.87 million in FY2026. AI-driven productivity gains are projected to save an additional $500,000 in expenses in FY2027. These measures support Global Health’s strategy to enhance operational profitability as the SaaS model matures and shifts from development to revenue scaling.
Strategic Focus on Revenue Scaling and Global Expansion
Following the completion of its platform upgrade, Global Health is pivoting toward scaling revenue and expanding internationally with its SaaS offerings, AI enhancements, and productivity platforms. The company plans to leverage AI-driven innovation to further boost customer productivity. Its SaaS platforms are globally accessible, and with new online sales channels and streamlined onboarding, management anticipates growing international revenue alongside domestic Australian sales in FY2027 and beyond.
The outlook considers healthcare providers in Australia facing funding and staffing pressures, alongside geopolitical and economic uncertainties globally, particularly in the Middle East. Global Health positions its SaaS and AI-enabled productivity solutions as cost-containment tools addressing these challenges. The rapid advancement of commercially available AI capabilities and associated productivity improvements are viewed as key drivers for healthcare providers to manage costs.
Positive Cash-Basis EBITDA and Profitability Outlook for FY2027
Global Health achieved positive cash-basis EBITDA after R&D expenses in both the March and June quarters of FY2026, marking a pivotal step toward sustainable operating profitability. The company aims to maintain EBITDA profitability and positive cash flow from FY2027 onward, reflecting confidence in the scalability of its SaaS model and cost efficiencies gained through AI adoption.
This milestone indicates the company’s core operations generate sufficient cash to cover expenses while continuing R&D investment. The explicit target for ongoing EBITDA profitability offers investors a clear benchmark for future performance evaluation.
Convertible Notes Redemption and Debt Strategy
During the reporting period, Global Health redeemed $100,000 of Convertible Notes using positive cash flow. The company is evaluating options for the remaining Convertible Notes maturing in June and July 2027, including repayment from free cash flow or refinancing with lower-cost non-convertible debt. This approach aligns with improved cash generation and the goal to lower capital costs as the business moves toward stable profitability.
Investors should monitor these upcoming maturities as they represent near-term financial milestones. While specific details on remaining convertible debt amounts or refinancing terms were not disclosed, successful management of these obligations will impact the company’s cash position and financial flexibility in FY2027.
Quarterly Operating Expenses and Related Party Payments
For the quarter ended 30 June 2026, Global Health’s operating expenses reported under ASX Listing Rule 4.7C included product manufacturing and operating costs of $844,000; staff costs of $1.322 million; administration and corporate expenses of $173,000; advertising and marketing costs of $26,000; and leased assets expenses of $40,000. The company did not provide a detailed R&D expense breakdown for the quarter, though full-year R&D spending was discussed narratively. Total product manufacturing and operating costs for the 12 months to June 2026 were $5.170 million, while staff costs amounted to $4.813 million.
Payments to related parties and associates during the June quarter totaled $81,800, solely comprising directors’ remuneration. This indicates limited related-party transactions and governance focused primarily on directors’ compensation. Staff costs remain the largest controllable expense and a key target for efficiency improvements driven by AI adoption.
AI Integration and Comprehensive Healthcare Software Portfolio
Global Health’s product suite includes case management, electronic medical records, practice management, patient engagement, and hospital operations software. The MasterCare Plus SaaS platform and MasterCare EMR on-premises application serve as core case management and EMR solutions. HotHealth’s digital front door patient portal and ReferralNet secure messaging extend capabilities to patient engagement and secure clinical communication. Lifecard Personal Health Record offers patients personal health management tools, while Theatre Management and Bed Flow platforms support hospital operational workflows.
The integration of the Heidi Scribe AI platform across multiple solutions underscores the company’s commitment to embedding AI-driven features. The Heidi Scribe AI platform is integrated into both MasterCare Plus SaaS and MasterCare EMR, with compliance and market release achieved. This aligns with the company’s strategy to prioritize AI-driven innovation, enhancing product differentiation and supporting international market expansion by addressing global healthcare cost pressures.
Healthcare Market Dynamics and Adoption Drivers
Global Health’s outlook is influenced by funding and staffing challenges faced by Australian healthcare providers, driving cost containment efforts. Additionally, geopolitical events and economic uncertainties, especially in the Middle East, impact healthcare provider behavior globally. The company positions its SaaS and AI-enabled productivity tools as solutions to these cost pressures.
The acceleration of commercially available AI capabilities is a critical market factor. Management highlights significant productivity gains from AI implementation as a natural solution for healthcare providers’ cost challenges. This suggests rising demand for software solutions focused on productivity and cost efficiency rather than service volume growth. Completion of the SaaS transition and AI integration positions Global Health to capitalize on this demand domestically and internationally through online sales and streamlined onboarding.
Technology Platform Migration and Customer Adoption Progress
In the June 2026 quarter, Global Health consolidated three client-server applications into a single multi-tenanted, configurable SaaS platform, establishing the foundation for shifting revenue from on-premises licenses to recurring subscriptions. Customer migration momentum was demonstrated by 5 new sites launching MasterCare Plus SaaS and 3 existing customers upgrading from legacy systems.
Development efforts included the Lifecard Personal Health Record UI/UX upgrade, expected for August 2026 release, and the launch of Theatre Management and Bed Flow platforms for hospital operations. These advancements indicate substantial progress in product modernization and readiness for customer acquisition and growth.
